FDA looks to resume domestic (US) inspections soon

August 25, 2020 As a safety measure, FDA will pre-announce all inspections, except for retail tobacco inspections, for the foreseeable future.  The announcement comes nearly two (2) months after the Agency said it will implement a phased approach to restarting surveillance inspections and four (4) months after the agency halted its domestic inspection program. However, … Read more

Abbott’s real-world data show FreeStyle Libre lowered A1c in Type 2 diabetes, with or without insulin

August 20, 2020 The observational study of Abbott’s FreeStyle Libre system, presented at the annual scientific sessions of the American Diabetes Association (ADA), pointed to an 0.8 percentage-point drop — from 8.5% to 7.7% — in overall A1c levels after six months of use.  After one year, that drop came to 0.6 percentage points.  According … Read more

Federal help falters as nursing homes run short of protective equipment

August 18, 2020 Some contain flimsy surgical masks or cloth face coverings that are explicitly not intended for medical use.  Others are missing items or have far less than the full weeks’ worth of protective equipment the government promised to send.  Instead of proper medical gowns, many packages hold large blue plastic ponchos.  “It’s like … Read more

FDA issues blanket COVID-19 authorization for IV infusion pumps

August 11, 2020 The move is similar to a previous Agency authorization issued in late March that broadly covered ventilators and respiratory devices, in a bid to quickly expand their supply against the pandemic.  That policy allowed alternative or modified devices to be used for ventilation, such as anesthesia gas machines, as long as they … Read more

Fitbit launches broad virtual AFib study using all its hear-tracking devices

August 06, 2020 But instead of testing one product, the Fitbit Heart Study plans to use several — including all of its current exercise trackers and smartwatches that can measure heart rate — to potentially enroll hundreds of thousands of people.  The trial’s results will serve as the foundation for the company’s regulatory submissions to … Read more

Hahn says COVID-19 vaccines will be reviewed in ‘real time’

August 04, 2020 Pfizer also announced at the end of July that it would begin a Phase 2/3 study of its COVID-19 vaccine developed in partnership with BioNTech.  Both companies say they plan to enroll 30,000 participants and expect a readout from their studies as early as this fall. Hahn’s remarks come as some observers … Read more

Diagnostic Makers Launch U.S. Test Registry To Target Covid-19 Hot Spots

July 30, 2020 The effort is a partnership of the Advanced Medical Technology Association (AdvaMed) and 13 of its member companies:  Abbott Laboratories; Becton Dickinson; bioMérieux; Bio-Rad; Beckman Coulter; Cepheid; Hologic; Ortho Clinical Diagnostics; Qiagen, Roche Diagnostics; Sekisui Diagnostics; Siemens Healthineers; and Thermo Fisher Scientific. Already, the companies involved are shipping more than 800,000 tests … Read more

Hahn testifies on COVID-19 response, says FDA on target to hit user fee goals

July 24, 2020 User fee goals, policy review Despite an “incredible surge in volume” of applications and constraints on the Agency’s ability to conduct inspections, Hahn said that FDA, “has maintained the same pace of meeting its goals on applications for medical products for the last six months that is has maintained in recent years.”  … Read more

Imaging Reveals Emerging Post-COVID Disease in Children

July 21, 2020 Known as Multisystem Inflammatory Syndrome in Children (MIS-C), this condition is characterized by airway inflammation, rapid development of pulmonary edema, coronary artery aneurysms, and extensive intra-abdominal inflammatory changes.  A team of investigators from Evelina London Children’s Hospital in London assessed these findings in children admitted to the hospital and published their findings … Read more

FDA finalizes contentious guidance on third party 510(k) reviews

July 16, 2020 Brief: The final guidance issued in March hews closely to the partly disputed draft, with the most common change being the adoption of 3P510k, rather than 3P, as the abbreviation for the program.  FDA did acquiesce to the pushback in some areas, for example by clarifying that review organizations should do assessments … Read more